Complement receptor 1 (CR1) and Alzheimer's disease

Area of Science:

• Neuroscience
• Immunology
• Genetics

Background:

• Alzheimer's disease (AD) is a leading neurodegenerative disorder, with late-onset AD (LOAD) having poorly understood genetic factors.
• The ε4 allele of Apolipoprotein E (APOE) was the primary known risk factor for LOAD until recent genome-wide association studies (GWAS).
• GWAS identified common genetic variants, including CLU and CR1, suggesting a role for the complement system in AD etiology.

Purpose of the Study:

• To review the evidence for complement system involvement in Alzheimer's disease (AD) pathogenesis.
• To specifically examine the role of the Complement Receptor 1 (CR1) gene in the complement cascade and its relation to AD.
• To discuss the impact of CR1 genetic polymorphisms on AD development and the amyloid cascade hypothesis.

Main Methods:

• Literature review of studies investigating the complement system in AD.
• Analysis of genetic association studies identifying risk factors for LOAD.
• Focus on CR1 gene polymorphisms and their functional implications.

Main Results:

• The complement system, particularly through genes like CLU and CR1, is implicated in the etiology of LOAD.
• CR1 acts as a receptor for complement fragments C3b and C4b and is expressed widely, including in circulation.
• Evidence suggests that genetic polymorphisms in CR1 may alter its function and contribute to AD pathogenesis.

Conclusions:

• The complement system plays a significant role in Alzheimer's disease.
• CR1 genetic polymorphisms are potential contributors to LOAD risk and progression.
• Further research into CR1's function is crucial for understanding AD pathogenesis and developing therapeutic strategies.